Arcturus Q2 revenue $27.1M, net loss $0.82/share; ARCT-154 booster shows durable Omicron response

Arcturus Therapeutics Holdings Inc.

2022-Q2 EPS reported -$2.75 revenue$32,337,000

Revenue $27.1M (vs $2.0M Q2 2021); net loss $21.6M ($0.82/sh) improved from $54.6M ($2.07/sh) year ago.
ARCT-154 booster: 44-fold (BA.1) and 39-fold (BA.2) neutralizing antibody GMFR at Day 91.
ARCT-810 gets EU Orphan Medicinal Product Designation for OTC deficiency; Phase 2 study enrolling.
ARCT-154 EUA in Vietnam delayed to Q4 2022; registrational booster study expected Q4 2022.
Cash $283.5M at June 30, down from $370.5M at Dec 2021; expected to fund ops into late 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.